LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) has announced the availability of its flagship supplement, Tru Niagen, at The Vitamin Shoppe and Super Supplements retail stores, as well as online. The expansion places the NAD+ boosting supplement in 700 additional locations across the United States, aiming to enhance consumer access to the product.
Tru Niagen contains NIAGEN (nicotinamide riboside or NR), a patented ingredient designed to support cellular health and vitality by increasing levels of NAD+, a vital coenzyme that naturally declines with age. The product is supported by over 30 human clinical studies and is backed by two Nobel Prize winners.
The President of The Vitamin Shoppe, Muriel Gonzalez, expressed excitement about offering Tru Niagen to customers seeking science-backed wellness solutions. The supplement will be featured in the longevity aisle and is available in both 30-count and 90-count bottles.
ChromaDex emphasizes the scientific rigor and quality standards behind Tru Niagen, which has been accepted by some of the world's most stringent regulatory bodies. The company's focus is on NAD+ and healthy aging research, with Tru Niagen being a significant part of its consumer product lineup.
The Vitamin Shoppe, a subsidiary of Franchise Group (NASDAQ:FRG), Inc., provides a wide range of nutritional solutions and is committed to lifelong wellness for its customers. The company operates approximately 700 retail stores in the United States and also serves customers globally through omnichannel partners.
ChromaDex's announcement of Tru Niagen's expanded distribution reflects the company's goal of increasing the accessibility of its products. This information is based on a press release statement from ChromaDex Corp.
InvestingPro Insights
As ChromaDex Corp. (NASDAQ:CDXC) broadens the retail presence of its Tru Niagen supplement, the company's financial health and stock performance are crucial for investors monitoring this expansion strategy. With a market capitalization of $256.62 million, ChromaDex is navigating the competitive supplement market with a focus on cellular health. While the company holds more cash than debt, an InvestingPro Tip suggests that analysts are not expecting ChromaDex to be profitable this year, reflecting the challenges it faces in achieving bottom-line growth.
Investors should note the volatility in ChromaDex's stock price, which has experienced a significant hit over the past week, with a price total return of -10.29%. However, looking at a longer horizon, the stock has shown a strong return over the last three months, with a total return of 131.29%. This kind of movement indicates a level of volatility that investors need to be aware of. Moreover, the stock's Price / Book ratio as of the last twelve months ending Q4 2023 stands at 9.02, which suggests that it is trading at a high multiple compared to its book value.
On the operational front, the company's revenue growth for the last twelve months as of Q4 2023 was 15.99%, which is a positive sign for investors looking for top-line expansion. Although ChromaDex is not currently profitable, it's important to highlight that its liquid assets exceed its short-term obligations, as noted in another InvestingPro Tip, providing some financial stability as it scales its distribution channels.
For those interested in a deeper analysis, there are additional InvestingPro Tips available at Investing.com. And for a limited time, users can take advantage of an exclusive offer by using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking further valuable insights into companies like ChromaDex.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.